Alluvi, previously BI 4744, represents a promising development in weight management treatment. This dual stimulator targeting both GLP-1 and GIP targets demonstrates remarkable efficacy in patient assessments, https://sparxsocial.com/story993487/alluvi-a-in-depth-dive-into-retatrutide-s-prospects